World journal of clinical oncology最新文献

{"title":"New research progress of sarcopenia in surgically resectable malignant tumor diseases.","authors":"Bing Fu, Lei Hu, Hui Ji, Ya-Feng Hou","doi":"10.5306/wjco.v16.i4.100309","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.100309","url":null,"abstract":"<p><p>With the aging global population, the decline in muscle mass and function among the elderly has emerged as a significant concern. This systemic progressive generalized loss of muscle function and mass is referred to as sarcopenia (SP). In recent years, a growing number of studies have investigated SP, revealing that many tumor diseases, especially in the digestive system, promote its occurrence due to the influence of the disease itself, diet, and other factors. Moreover, SP patients tend to have poorer postoperative recovery. At present, many diagnostic methods have been developed for SP, but no unified standard has been established. Furthermore, the cutoff values of many diagnostic methods for different populations are still in the exploratory stage, and additional clinical studies are required to explore these issues. This article comprehensively and systematically summarizes the diagnostic methods and criteria mentioned in previous research, focusing on the impact of SP on post-surgical patients with various malignant tumors.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"100309"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxaliplatin-induced diffuse alveolar hemorrhage: A case report.","authors":"Toshiaki Tsurui, Emiko Mura, Atsushi Horiike, Takuya Tsunoda","doi":"10.5306/wjco.v16.i4.105077","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.105077","url":null,"abstract":"<p><strong>Background: </strong>Drug-induced lung injury is a common adverse effect of chemotherapeutic agents. Diffuse alveolar hemorrhage (DAH) is a fatal complication associated with drug-induced lung injury. Early diagnosis and treatment of DAH is critical, as delayed management can lead to respiratory failure and poor outcomes. However, the diagnosis of DAH is difficult because of the nonspecific clinical manifestations; as such, bronchoscopy is necessary to establish a diagnosis.</p><p><strong>Case summary: </strong>The patient presented with fever and dry cough. He had been receiving fluoropyrimidine and oxaliplatin therapy for esophageal squamous cell carcinoma. Chest imaging revealed diffuse ground-glass opacities. Bronchoscopy with bronchoalveolar lavage was performed, which confirmed the diagnosis of DAH. Although the patient's respiratory status rapidly worsened, high-dose corticosteroid therapy with respiratory support gradually improved the patient's condition and he was successfully extubated.</p><p><strong>Conclusion: </strong>Prompt DAH diagnosis and bronchoscopy in patients receiving oxaliplatin-containing chemotherapy presenting with acute respiratory failure are critical for improving outcomes.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"105077"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of the preoperative systemic immune-inflammation nutritional index in patients with gastric cancer.","authors":"Li-Jing Wang, Cai-Lu Lei, Ting-An Wang, Zhi-Feng Lin, Shi-Jie Feng, Tao Wei, Yan-Qin Li, Meng-Ru Shen, Yan Li, Liu-Feng Liao","doi":"10.5306/wjco.v16.i4.102294","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102294","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is the fifth most common cancer and the third leading cause of cancer-related deaths in China. Many patients with GC frequently experience symptoms related to the disease, including anorexia, nausea, vomiting, and other discomforts, and often suffer from malnutrition, which in turn negatively affects perioperative safety, prognosis, and the effectiveness of adjuvant therapeutic measures. Consequently, some nutritional indicators such as nutritional risk index (NRI), prognostic nutritional index (PNI), and systemic immune-inflammatory-nutritional index (SIINI) can be used as predictors of the prognosis of GC patients.</p><p><strong>Aim: </strong>To examine the prognostic significance of PNI, NRI, and SIINI in postoperative patients with GC.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical data of patients with GC who underwent surgical treatment at the Guangxi Medical University Cancer Hospital between January 2010 and December 2018. The area under the receiver operating characteristic (ROC) curve was assessed using ROC curve analysis, and the optimal cutoff values for NRI, PNI, and SIINI were identified using the You-Review-HTMLden index. Survival analysis was performed using the Kaplan-Meier method. In addition, univariate and multivariate analyses were conducted using the Cox proportional hazards regression model.</p><p><strong>Results: </strong>This study included a total of 803 patients. ROC curves were used to evaluate the prognostic ability of NRI, PNI, and SIINI. The results revealed that SIINI had superior predictive accuracy. Survival analysis indicated that patients with GC in the low SIINI group had a significantly better survival rate than those in the high SIINI group (<i>P</i> < 0.05). Univariate analysis identified NRI [hazard ratio (HR) = 0.68, 95% confidence interval (CI): 0.52-0.89, <i>P</i> = 0.05], PNI (HR = 0.60, 95%CI: 0.46-0.79, <i>P</i> < 0.001), and SIINI (HR = 2.10, 95%CI: 1.64-2.69, <i>P</i> < 0.001) as prognostic risk factors for patients with GC. However, multifactorial analysis indicated that SIINI was an independent risk factor for the prognosis of patients with GC (HR = 1.65, 95%CI: 1.26-2.16, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Analysis of clinical retrospective data revealed that SIINI is a valuable indicator for predicting the prognosis of patients with GC. Compared with NRI and PNI, SIINI may offer greater application for prognostic assessment.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102294"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating pregabalin in cancer patients with chronic neuropathic pain and depression: an observational case series.","authors":"Pinaki Chakraborty, Mrinal Borgohain","doi":"10.5306/wjco.v16.i4.104827","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104827","url":null,"abstract":"<p><strong>Background: </strong>Chronic neuropathic pain and depression are common and debilitating conditions in cancer patients, significantly impacting their quality of life. Pregabalin, an anticonvulsant medication, is used for neuropathic pain and may also influence depressive symptoms. This study evaluates the efficacy and safety of pregabalin on pain intensity, depression severity, and side effects in cancer patients with chronic neuropathic pain and depression.</p><p><strong>Aim: </strong>To evaluate the impact of pregabalin on pain intensity, depression severity, and the safety profile in cancer patients with chronic neuropathic pain and depression.</p><p><strong>Methods: </strong>This observational case series included 10 cancer patients experiencing chronic neuropathic pain and depression. Pregabalin was administered at a starting dose of 150 mg twice daily, with adjustments based on patient tolerance and pain response up to 300 mg twice daily. Pain intensity and depression severity were assessed using the brief pain inventory (BPI) and the Hamilton depression rating scale (HDRS) at baseline, 4 weeks, and 8 weeks. Side effects were monitored using a self-reported side effect questionnaire.</p><p><strong>Results: </strong>Pregabalin led to a significant reduction in pain intensity and depression severity. The mean BPI score decreased from 7.8 (SD = 1.2) at baseline to 5.2 (SD = 1.4) at 4 weeks and 4.1 (SD = 1.5) at 8 weeks, representing reductions of 33.3% and 47.4%, respectively. The mean HDRS score decreased from 18.5 (SD = 4.0) at baseline to 13.2 (SD = 4.1) at 4 weeks and 9.8 (SD = 3.6) at 8 weeks, showing reductions of 28.4% and 47.0%, respectively. Side effects included dizziness (50%), drowsiness (40%), weight gain (30%), and dry mouth (20%). No severe adverse effects were reported. All patients completed the study, with 30% requiring dose adjustments.</p><p><strong>Conclusion: </strong>Pregabalin significantly alleviates both chronic neuropathic pain and depression in cancer patients with a manageable safety profile. These findings support the use of pregabalin in this patient population, though further research with larger samples and controlled designs is warranted.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104827"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of comprehensive geriatric assessment in oncology nursing: A literature review on optimizing treatment decisions and patient outcomes.","authors":"Cheng-Jin Li, Shu-Mei Gong, Yu-Juan Shi, Ya-Nan Guo, Na-Na Song, Li-Min Jiang, Yan-Yan Wang, Chang-Jiang Zhang, Yao-Bin Wang, Zhi-Peng Li, Peng Wang, Yu-Hua Ruan, Zhen Shi, Hao-Yu Li, Qiu-Jun Zhang, Wei-Ping Fu","doi":"10.5306/wjco.v16.i4.104785","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104785","url":null,"abstract":"<p><p>With the global population aging, the care of elderly cancer patients has become increasingly complex and significant. Comprehensive geriatric assessment (CGA), a multidimensional evaluation tool, has been widely implemented in oncology nursing to enhance the precision of treatment decisions and improve patient outcomes. This review examines the application of CGA in oncology nursing, drawing on literature published between 2010 and 2024 in major databases using keywords such as \"Comprehensive Geriatric Assessment\" and \"Oncology Nursing\". It highlights how CGA contributes to optimizing treatment selection, monitoring the treatment process, and improving patients' quality of life and long-term outcomes. CGA provides a comprehensive evaluation of elderly cancer patients, including physical, psychological, and social aspects, enabling the identification of high-risk patients and reducing treatment-related side effects and complications. It also offers a critical foundation for developing personalized care plans. The article discusses various practical examples of CGA implementation across different countries and regions, including multidisciplinary collaborative models in France, the United States, and Australia, demonstrating CGA's flexible application in diverse healthcare settings. Although significant progress has been made in applying CGA in oncology nursing, numerous challenges remain in its implementation, such as resource limitations and insufficient personnel training. Future research will focus on integrating CGA with emerging technologies, such as artificial intelligence and precision medicine, to further improve the quality of care and treatment outcomes for elderly cancer patients. By summarizing the current status and challenges of CGA in oncology nursing, this review provides guidance for future research and clinical practice, emphasizing the importance of advancing CGA application to meet the growing demands of elderly oncology care.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104785"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of the mechanisms of the biliary-enteric axis in the development of cholangiocarcinoma.","authors":"Tian-Hao Shen, Xue Yu, Cheng Zhou, Yu Liu, Qiu-Ying Li, Wei Li, Ting-Hui Jiang, Yong-Qiang Zhu, Yan Liu","doi":"10.5306/wjco.v16.i4.102374","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102374","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a particularly aggressive and challenging type of cancer, known for its poor prognosis, which is worsened by the complex interplay of various biological and environmental factors that contribute to its development. Recently, researchers have increasingly focused on the significant role of the biliary-enteric communication of liver-gut axis in the pathogenesis of CCA, highlighting a complex relationship that has not been thoroughly explored before. This review aims to summarize the key concepts related to the biliary-enteric communication of liver-gut axis and investigate its potential mechanisms that may lead to the onset and progression of CCA, a disease that presents substantial treatment challenges. Important areas of focus will include the microbiome's profound influence, which interacts with host physiology in ways that may worsen cancer development; changes in bile acid metabolism that can create toxic environments favorable for tumor growth; the regulation of inflammatory processes that may either promote or inhibit tumor progression; the immune system's involvement, which is crucial in the body's response to cancer; and the complex interactions within metabolic pathways that can affect cellular behavior and tumor dynamics. By integrating recent research findings from various studies, we aim to explore the multifaceted roles of the biliary-enteric communication of liver-gut axis in CCA, providing new insights and perspectives for future research while identifying promising therapeutic targets that could lead to innovative treatment strategies aimed at improving patient outcomes in this challenging disease.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102374"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current status and recent progress of nanomaterials in transcatheter arterial chemoembolization therapy for hepatocellular carcinoma.","authors":"Jia Sun, Hai-Liang Li, Wen-Jun Zhou, Zeng-Xin Ma, Xiao-Pei Huang, Cheng Li","doi":"10.5306/wjco.v16.i4.104435","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104435","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) remains one of the most common cancers worldwide. Transcatheter arterial chemoembolization has become a common treatment modality for some patients with unresectable advanced HCC. Since the introduction of nanomaterials in 1974, their use in various fields has evolved rapidly. In medical applications, nanomaterials can serve as carriers for the delivery of chemotherapeutic drugs to tumour tissues. Additionally, nanomaterials have potential for <i>in vivo</i> tumour imaging. This article covers the properties and uses of several kinds of nanomaterials, focusing on their use in transcatheter arterial chemoembolization for HCC treatment. This paper also discusses the limitations currently associated with the use of nanomaterials.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104435"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging salivary biomarkers for early detection of oral squamous cell carcinoma.","authors":"Cheng-Chen Hu, Sheng-Guo Wang, Zhi Gao, Mao-Feng Qing, Shan Pan, Ying-Ying Liu, Fang Li","doi":"10.5306/wjco.v16.i4.103803","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.103803","url":null,"abstract":"<p><p>Oral cancer, particularly oral squamous cell carcinoma (OSCC), remains a leading cause of cancer-related morbidity and mortality, with delayed diagnosis being a major contributing factor. Although salivary biomarkers have been explored for over three decades, the need for reliable, non-invasive diagnostic methods that enable early detection and continuous monitoring of OSCC remains unmet. This review aims to provide an updated overview of the latest advancements in salivary biomarker research, focusing on emerging biomarkers such as interleukin-6, interleukin-8, microRNAs and DNA methylation patterns, as well as metabolites and microbiota, all of which show significant promise for early OSCC detection. In addition to discussing well-established biomarkers, we explore recent technological developments that increase the sensitivity and specificity of these biomarkers, such as mass spectrometry, multiplex assays, and nanobiosensors. These developments are complemented by the integration of artificial intelligence for data analysis, which enables more accurate, point-of-care diagnostics that could revolutionize oral cancer screening. This review not only consolidates current knowledge but also addresses the challenges that hinder the widespread clinical adoption of salivary diagnostics, such as saliva variability and assay standardization. By overcoming these barriers, salivary biomarker-based diagnostics have the potential to transform OSCC detection, offering a non-invasive, cost-effective solution that can improve early diagnosis and patient outcomes.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"103803"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and treatment of pulmonary lymphoepithelioma-like carcinoma: A case report.","authors":"Feng-Ling Huang, Min Luo, Zhen-Mei He, Yong-Qi Shen, Guan-Da Liu","doi":"10.5306/wjco.v16.i4.104413","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.104413","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare primary epithelial lung cancer associated with the Epstein-Barr virus. Standard treatment guideline for PLELC is yet not to be established, surgery remains the primary treatment for early-stage PLELC, and platinum chemotherapy is the most common first-line treatment for advanced PLELC. While targeted therapy and immunotherapy has emerged as effective way to treat various malignant tumors, including lung cancer, reports on PLELC are relatively scarce.</p><p><strong>Case summary: </strong>A 38-year-old man was diagnosed with right PLELC. Chest computed tomography (CT) revealed a mass in the medial segment of the middle lobe of the right lung, with lymph node metastasis in the mediastinum and right hilum of the lung. CT-guided lung tumor biopsy was performed and the postoperative pathological examination combined with immune phenotype analysis and in situ hybridization confirmed PLELC. Standard molecular testing for patients with non-small cell lung cancer was negative and programmed cell death ligand-1 expression was about 2%. The patient declined radiotherapy and chemotherapy. Consequently, immunotherapy was administered, which included toripalimab 240 mg on day 1 and anlotinib 10 mg on days 1-14 for 10 cycles, followed by a maintenance dose of anlotinib 10 mg daily every 3 weeks. As a result, his progression-free survival reached 48 months.</p><p><strong>Conclusion: </strong>A combination of toripalimab and anlotinib may benefit patients with advanced diseases who have not received systematic antitumor therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"104413"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between <i>Helicobacter pylori</i> infection and programmed death-ligand 1 in gastric cancer: A meta-analysis.","authors":"Hong-Chang Yang, Cheng-Feng Fu, Li-Jun Qiao, Gen-He Long, Li-Fen Yang, Biao Yao","doi":"10.5306/wjco.v16.i4.102397","DOIUrl":"https://doi.org/10.5306/wjco.v16.i4.102397","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is one of the most common malignancies worldwide, and <i>Helicobacter pylori</i> (HP) infection is a well-established risk factor for its development. Programmed death-ligand 1 (PD-L1) expression is a crucial biomarker for predicting the efficacy of immune checkpoint inhibitors in cancer treatment. While HP infection and PD-L1 expression in GC may be linked, the relationship between them remains unclear, in part because there have been conflicting results reported from various studies.</p><p><strong>Aim: </strong>To perform a meta-analysis to assess the relationship between HP and PD-L1 expression in patients with GC.</p><p><strong>Methods: </strong>A systematic literature review was conducted using PubMed, Embase, Cochrane Library, and Web of Science databases. Observational studies that examined the association between HP infection and PD-L1 expression in patients with GC were included. Odds ratios and 95% confidence intervals were calculated to estimate the association. Heterogeneity was assessed using Cochrane's <i>Q</i> test and <i>I²</i> statistic. A random-effects model was used due to significant heterogeneity across studies.</p><p><strong>Results: </strong>Fourteen studies involving a total of 3069 patients with GC were included. The pooled analysis showed a significant association between HP infection and increased PD-L1 expression in GC tissues (odd ratio = 1.69, 95% confidence interval: 1.24-2.29, <i>P</i> < 0.001, <i>I</i> ² = 59%). Sensitivity analyses confirmed the robustness of these findings. Subgroup analyses did not show significant variation based on geographic region, sample size, or method of PD-L1 assessment. Publication bias was minimal, as shown by funnel plots and Egger's regression test.</p><p><strong>Conclusion: </strong>HP infection is associated with increased PD-L1 expression in GC, suggesting that HP status may influence the response to programmed cell death protein 1/PD-L1 blockade therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 4","pages":"102397"},"PeriodicalIF":2.6,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12019281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}